This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D44 (Neoplasm of uncertain or unknown behavior of endocrine glands) | Special Copayment Reduction: V193 (Special Copayment Reduction for cancer: copayment 5% for 5 years from the registration date) |
| B. Synonyms | Thyroid neoplasm of uncertain behavior (D44.0), adrenal tumor of uncertain behavior (D44.1, including pheochromocytoma), parathyroid of uncertain behavior (D44.2), pituitary of uncertain behavior (D44.3), craniopharyngioma (D44.4), pineal of uncertain behavior (D44.5), MEN syndrome-associated tumors |
| C. Adult onset | Adrenal incidentalomas and pituitary incidentalomas are commonly found on imaging in adults and are mostly nonfunctioning. Pheochromocytoma can occur at any age but is most common in the 30s~50s. |
| 1. History | The history of endocrine oncology began with the recognition of endocrine organs in the late 19th century and was modernized through the characterization of MEN syndromes and the discovery of the VHL gene. |
| 2. Causes | MEN1/MEN2 syndromes, VHL disease, SDH mutations, radiation exposure, and exogenous hormones are the main risk factors, though sporadic cases are more common. |
| 3. Genetics | MEN1 (11q13), RET (10q11), VHL (3p25), SDH (A/B/C/D), CDKN1B, and MAX gene mutations are the key genes of hereditary endocrine tumors. |
| 4. General epidemiology | Adrenal incidentalomas are found in about 3~5% of adults undergoing CT; pituitary incidentalomas in about 10~15%. Pheochromocytoma occurs in about 2~8 per 100,000. |
| 5. Pathophysiology | Abnormalities of the pseudohypoxia pathway (SDH and VHL mutations → HIF-1α stabilization) and kinase signaling pathway (RET, MEN1 → PI3K/mTOR) are the two main pathogenic axes. |
| 6. Symptoms | Various symptoms due to hormone hypersecretion or compression; typical examples are the triad of headache, hypertension, and sweating in pheochromocytoma, the Cushing syndrome phenotype, and mass-effect symptoms of pituitary tumors. |
| 7. Signs | Obesity and moon face (Cushing), paroxysmal hypertension and tachycardia (pheochromocytoma), visual field defects and headache (pituitary), signs of hypercalcemia (parathyroid), acral enlargement (acromegaly). |
| 8. Screening | Regular biochemical testing and imaging follow-up in families with MEN1, MEN2, and VHL syndromes; urine screening tests for pheochromocytoma are recommended in hypertensive patients. |
| 9. Diagnosis | Endocrine function tests, CT, MRI, 68Ga-DOTATATE PET-CT (neuroendocrine tumors), MIBG scan, and gene panel testing are the key diagnostic tools. |
| 10. Treatment | Surgical resection is the first-line treatment for most endocrine neoplasms; medical therapy such as dopamine agonists and somatostatin analogues is used for pituitary tumors. |
| 11. Prognosis | Adrenal and pituitary incidentalomas mostly have a benign course; pheochromocytoma is malignant in about 10~17%; MEN-associated tumors vary by genotype. |
| 12. Prevention | Early genetic diagnosis of hereditary syndromes, regular biochemical and imaging follow-up, and prophylactic thyroidectomy in RET-mutant MEN2 are the key prevention strategies. |
| 13. References | Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis … and 9 other papers |
The history of endocrine gland oncology begins in the late 19th century as the functions of the endocrine organs were successively elucidated. In 1855, Thomas Addison described adrenal insufficiency, and in 1896, George Oliver and Edward Sharpey-Schafer discovered the pressor effect of adrenal extract (adrenaline). In the 1920s, tumors originating in the adrenal gland (pheochromocytoma) began to be recognized clinically, and in 1926 Charles Mayo performed the first successful pheochromocytoma resection.
The history of multiple endocrine neoplasia (MEN) begins with Erdheim's 1903 report of simultaneous hyperplasia of several endocrine glands. In 1954, Paul Werner systematized the co-occurrence of parathyroid, pituitary, and pancreatic islet cell tumors as "MEN type 1 (Werner syndrome)". In 1961, John Sipple described the co-occurrence of medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia, which was later named "MEN type 2". The MEN1 gene (long arm of chromosome 11) was identified in 1997 and RET (the MEN2-associated proto-oncogene) in 1993.
The classification of pituitary tumors was founded on the work of Harvey Cushing in the early 1900s. Cushing first described Cushing disease (pituitary ACTH-secreting tumor) and classified pituitary adenomas clinically and histologically. The concept of adrenal incidentaloma emerged after the spread of CT in the 1980s, and guidelines for evaluating adrenal incidentalomas were subsequently published by several societies. The 2022 revised WHO classification of endocrine tumors (5th edition) expanded the introduction of molecularly based classification of endocrine neoplasms.
The causes of D44 neoplasms of uncertain behavior of endocrine glands are divided into hereditary and sporadic. MEN1 syndrome is an autosomal dominant disorder caused by germline mutations of the MEN1 gene (11q13), characteristically accompanied by parathyroid hyperplasia/adenoma, pituitary adenoma (mainly prolactinoma or nonfunctioning adenoma), pancreatic and duodenal neuroendocrine tumors, and bronchial carcinoid. Endocrine tumors in MEN1 patients occur at a much younger age (20s~30s) than in the general population. MEN2A/2B is caused by germline mutations of the RET proto-oncogene and is characterized by medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia (MEN2A).
In VHL (von Hippel-Lindau) syndrome, VHL gene (3p25) mutations cause pheochromocytoma, paraganglioma, clear cell renal carcinoma, retinal hemangioma, and central nervous system hemangioblastoma. SDH (succinate dehydrogenase) gene mutations (SDHA/B/C/D) are an important genetic cause of pheochromocytoma and paraganglioma. MAX gene mutations and TMEM127 mutations are also associated with hereditary pheochromocytoma. Radiation, especially after head and neck radiation therapy, is associated with hypopituitarism and the development of thyroid tumors of uncertain behavior. Exogenous estrogen and progestin administration can promote the growth of pituitary adenomas, especially prolactinomas.
The genetics of neoplasms of uncertain behavior of endocrine glands differ by site, but several syndromes share overlapping gene pathways. The MEN1 gene encodes the nuclear protein menin, which is involved in regulating histone methylation, and its loss of function results in multiple endocrine gland tumors. Menin binds to the MLL/KMT2A histone methyltransferase complex to regulate transcription of tumor suppressor genes, and its loss of function promotes CDK4/6-dependent cell cycle progression.
In pheochromocytoma, mutations in the SDH complex genes play a central role. Loss of SDH function causes accumulation of succinate, which inhibits 2-oxoglutarate (2-OG)-dependent dioxygenases (TET2, EGLN, etc.), thereby stabilizing HIF-1α. As a result, angiogenic factors (VEGF) are overexpressed and a pseudohypoxic state is induced, promoting tumor growth. In pituitary adenomas, CDKN1B (p27Kip1) mutations cause a MEN1 syndrome-like phenotype (MEN4), and AIP gene mutations are important in familial isolated pituitary adenoma (FIPA). CDC73 (HRPT2) gene mutations, PRKAR1A mutations (associated with Carney complex), and MEN1 mutations are found in parathyroid carcinoma.
The epidemiology of neoplasms of uncertain behavior of endocrine glands differs greatly by type. Adrenal incidentaloma is a very common incidental lesion found in about 3~5% of adults undergoing abdominal CT. It increases with age and is observed in about 10% of people in their 70s or older. About 70~80% of adrenal incidentalomas are nonfunctioning adrenal adenomas, about 5% are pheochromocytomas, about 1~2% are adrenocortical carcinomas, and about 2% are metastatic lesions. Therefore, assessment of function and malignancy is essential for a newly found adrenal incidentaloma.
Pituitary incidentalomas are found in about 10~15% of adults undergoing MRI, and most (about 90%) are microadenomas less than 10mm in diameter. Pituitary macroadenomas (>10mm) are rare, found in about 0.2%. The incidence of pheochromocytoma is about 2~8 per 100,000 per year, and it is found in about 0.2~0.4% of all hypertensive patients. About 30~40% of pheochromocytomas are hereditary (SDH, VHL, RET, NF1, etc.), and the rest are sporadic. The prevalence of MEN1 syndrome is about 1~3 per 100,000 population, and prevalence data from Asia, including Korea, are limited.
The pathogenesis of neoplasms of uncertain behavior of endocrine glands is broadly divided into two main molecular pathways. The pseudohypoxic pathway is triggered by SDH, VHL, FH, and MDH2 gene mutations. With loss of SDH or VHL function, HIF-1α is stabilized even in the presence of oxygen, and hypoxia-response genes such as VEGF (vascular endothelial growth factor), EPO (erythropoietin), and GLUT1 are overexpressed. This promotes strong angiogenesis and a shift in glucose metabolism, creating a microenvironment that supports rapid tumor growth.
Abnormalities of kinase signaling pathways are triggered by RET (MEN2), NF1, and MAX mutations. Activating RET mutations simultaneously activate the PI3K/AKT/mTOR and RAS/MAPK pathways, causing unregulated proliferation of endocrine cells (thyroid medullary C cells, adrenal medullary chromaffin cells). Loss of MEN1/menin function reduces histone H3K4 methylation, decreasing expression of CDK inhibitors such as CDKN1B and CDKN2C and promoting cell cycle progression from G1 → S phase. In the development of adrenocortical tumors, the WNT/β-catenin pathway (CTNNB1 mutations), PRKAR1A mutations (cAMP-PKA pathway), and IGF-2 overexpression play important roles.
The symptoms of D44 neoplasms of uncertain behavior of endocrine glands vary greatly with hormone secretion and tumor location and size. In functioning tumors, syndromes appear according to the characteristics of the hormone secreted in excess. The classic triad of pheochromocytoma is headache, sweating, and palpitations; when all three are present, pheochromocytoma is likely. Blood pressure presents as sustained hypertension (50%) or paroxysmal hypertension (50%), and during a hypertensive crisis headache, profuse sweating, pounding heart, and anxiety accompany it. In Cushing syndrome (adrenal ACTH-independent cortisol excess), weight gain (central obesity), skin striae, elevated blood glucose, muscle weakness, and mood changes appear.
In pituitary adenomas, various symptoms of hormone hypersecretion appear depending on the tumor type. Prolactinomas cause amenorrhea and galactorrhea in women, and sexual dysfunction and gynecomastia in men. Growth hormone-secreting adenomas cause acromegaly (enlargement of bone, soft tissue, tongue, nose, hands and feet, change in facial appearance). Adrenocorticotropic hormone (ACTH)-secreting tumors cause Cushing syndrome. When the tumor is large, compression of surrounding structures causes visual field defects (bitemporal hemianopia due to optic chiasm compression), headache, and ophthalmoplegia (cavernous sinus invasion). Nonfunctioning tumors present mainly with compressive symptoms from increasing size and hypopituitarism (hypothyroidism, adrenal insufficiency, hypogonadism).
On physical examination in pheochromocytoma, hypertension (systolic > 200mmHg possible), profuse sweating during attacks, pallor followed by flushing, and orthostatic hypotension are found. On palpation of the thyroid region, a neck mass may be found, and in medullary thyroid carcinoma a firm nodule with irregular margins is palpable. In hyperparathyroidism (hypercalcemia), muscle weakness, decreased deep tendon reflexes, Chvostek and Trousseau signs (negative in hypercalcemia, positive in hypocalcemia), and psychiatric symptoms (confusion, lethargy) appear. Typical physical signs of Cushing syndrome include moon face, buffalo hump (fat accumulation in the neck), purple abdominal striae, proximal muscle atrophy, and thinning of the skin.
In patients with acromegaly, enlarged hands and feet, mandibular prognathism, diastema, thickened skin, a deep voice due to enlargement of the subglottic region, and snoring and sleep apnea are observed. In pituitary macroadenoma, bitemporal hemianopia is characteristically found on visual field testing. In patients with hypopituitarism, signs of panhypopituitarism such as pale skin, dry skin, bradycardia, myxedematous face, and reduced pubic and axillary hair are observed.
The key to screening for neoplasms of uncertain behavior of endocrine glands is a targeted approach directed at high-risk groups rather than the general population. In patients with confirmed MEN1 syndrome and their families, for carriers of pathogenic variants, regular biochemical testing (calcium, PTH, prolactin, IGF-1, fasting glucose/insulin, gastrin) and imaging follow-up (annual abdominal CT/MRI, brain MRI every 3 years) of the parathyroid, pituitary, and pancreas are recommended from a young age (around age 10). In MEN2A variant carriers, the timing of prophylactic thyroidectomy is determined by the type of RET mutation, and regular serum calcitonin and catecholamine tests are performed.
In patients newly diagnosed with pheochromocytoma, even if it appears sporadic, identification of a hereditary cause through SDH, VHL, RET, NF1, MAX, and TMEM127 gene testing is recommended (currently about 30~40% are hereditary). Families of confirmed hereditary pheochromocytoma carriers need genetic counseling along with follow-up by regular plasma metanephrine measurement and abdominal MRI. In hypertensive patients whose blood pressure is difficult to control or accompanied by paroxysmal elevations, or who have an adrenal incidentaloma, pheochromocytoma is screened with plasma or 24-hour urine metanephrine testing. For adrenal incidentalomas, function and malignancy are evaluated immediately upon discovery with hormone testing (cortisol suppression test, blood catecholamines/metanephrines, aldosterone/renin ratio) and imaging characteristic analysis (HU value < 10 strongly suggests adenoma).